SANA
Sana Biotechnology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SANA
Sana Biotechnology, Inc.
A company focused on creating and delivering engineered cells as medicines
188 East Blaine Street, Suite 400, Seattle, Washington 98102
--
Sana Biotechnology, Inc., was incorporated in Delaware on July 13, 2018. The company is developing in vitro and in vivo cell engineering platforms to revolutionize a range of therapeutic areas with unmet therapeutic needs, including oncology, diabetes, central nervous system diseases, cardiovascular diseases and genetic diseases, among others. Clinical data from the company's first project, the CD19 Targeted Alien Chimeric Antigen Receptor (CAR) T (SC 291) project, is expected to be released in 2023. The company is also making progress in developing cell engineering platforms and advancing product candidates through preclinical development, with the goal of submitting multiple investigational new drugs in 2023 and beyond.
Company Financials
EPS
SANA has released its 2025 Q3 earnings. EPS was reported at -0.15, versus the expected -0.19, beating expectations. The chart below visualizes how SANA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
